Ensem Therapeutics Doses First Patient in China in ETX-636 Global Phase 1/2 Study - BioSpace

2026-02-02 - 19:45

Ensem Therapeutics Doses First Patient in China in ETX-636 Global Phase 1/2 Study BioSpace